BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 17679790)

  • 1. Application of recent definitions of the metabolic syndrome to survey data from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE II).
    Deedwania PC; Maki KC; Dicklin MR; Stone NJ; Ballantyne CM; Davidson MH
    J Cardiometab Syndr; 2006; 1(5):295-300. PubMed ID: 17679790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dyslipidemia in the metabolic syndrome in children.
    Gidding SS
    J Cardiometab Syndr; 2006; 1(4):282-5. PubMed ID: 17679808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations.
    Davidson MH; Maki KC; Pearson TA; Pasternak RC; Deedwania PC; McKenney JM; Fonarow GC; Maron DJ; Ansell BJ; Clark LT; Ballantyne CM
    Am J Cardiol; 2005 Aug; 96(4):556-63. PubMed ID: 16098311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of Canadian and American guidelines for lipid management using data from the National Cholesterol Education Program Evaluation ProjecT Utilizing Novel E-technology (NEPTUNE) II survey.
    Maki KC; Davidson MH; Dicklin MR
    Can J Cardiol; 2006 Mar; 22(4):315-22. PubMed ID: 16568156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of metabolic syndrome in Japanese-Brazilians according to specific definitions for ethnicity.
    Xavier NP; Chaim RC; Gimeno SG; Ferreira SR; Hirai AT; Padovani CR; Okoshi MP; Okoshi K
    Metab Syndr Relat Disord; 2010 Apr; 8(2):143-8. PubMed ID: 19900161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Management of Dyslipidaemia in Patients with Type 2 Diabetes Mellitus Receiving Lipid-Lowering Drugs: A Sub-Analysis of the CEPHEUS Findings.
    Shehab A; Al-Rasadi K; Arafah M; Al-Hinai AT; Al Mahmeed W; Bhagavathula AS; Al Tamimi O; Al Herz S; Al Anazi F; Al Nemer K; Metwally O; Alkhadra A; Fakhry M; Elghetany H; Medani AR; Yusufali AH; Al Jassim O; Al Hallaq O; Baslaib FOAS; Alawadhi M; Amin H; Al-Hashmi K; Oulhaj A
    Curr Vasc Pharmacol; 2018; 16(4):368-375. PubMed ID: 28677510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Prevalence, Awareness, Treatment, and Control of Cardiovascular Risk Factors in China and the United States.
    Lu Y; Wang P; Zhou T; Lu J; Spatz ES; Nasir K; Jiang L; Krumholz HM
    J Am Heart Assoc; 2018 Jan; 7(3):. PubMed ID: 29374046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of age and sex with cardiovascular risk factors and insulin sensitivity in overweight children and adolescents.
    Koenigsberg J; Boyd GS; Gidding SS; Hassink SG; Falkner B
    J Cardiometab Syndr; 2006; 1(4):253-8. PubMed ID: 17679813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: the Strong Heart Study.
    de Simone G; Devereux RB; Chinali M; Best LG; Lee ET; Galloway JM; Resnick HE;
    Diabetes Care; 2007 Jul; 30(7):1851-6. PubMed ID: 17440172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of coronary heart disease risk assessments among individuals with metabolic syndrome using three diagnostic definitions: a cross-sectional study from China.
    Zhou J; Gao Q; Wang J; Zhang M; Ma J; Wang C; Chen H; Peng X; Hao L
    BMJ Open; 2018 Oct; 8(10):e022974. PubMed ID: 30366915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The metabolic syndrome as a prohypertensive state.
    Mulé G; Cerasola G
    Am J Hypertens; 2008 Jan; 21(1):8. PubMed ID: 18268791
    [No Abstract]   [Full Text] [Related]  

  • 12. Preventing cardiovascular disease and diabetes: a call to action from the ADA and AHA.
    Wyne KL
    J Cardiometab Syndr; 2006; 1(3):220-1. PubMed ID: 17679801
    [No Abstract]   [Full Text] [Related]  

  • 13. Does the prevalence of the metabolic syndrome improve by applying the International Diabetes Federation criteria?
    Soto González A; Bellido Guerrero D; Buño Soto M; Pértega Díaz S; De Luis D; Lopez de la Torre M; Martínez Olmos M
    Public Health Nutr; 2007 Oct; 10(10A):1173-80. PubMed ID: 17903327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic syndrome in Mexican adults: results from the National Health and Nutrition Survey 2006.
    Rojas R; Aguilar-Salinas CA; Jiménez-Corona A; Shamah-Levy T; Rauda J; Avila-Burgos L; Villalpando S; Ponce EL
    Salud Publica Mex; 2010; 52 Suppl 1():S11-8. PubMed ID: 20585723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Definitions of metabolic syndrome: Where are we now?
    Daskalopoulou SS; Athyros VG; Kolovou GD; Anagnostopoulou KK; Mikhailidis DP
    Curr Vasc Pharmacol; 2006 Jul; 4(3):185-97. PubMed ID: 16842136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of different definitions of the metabolic syndrome on the prevalence of organ damage, cardiometabolic risk and cardiovascular events.
    Mancia G; Bombelli M; Facchetti R; Casati A; Ronchi I; Quarti-Trevano F; Arenare F; Grassi G; Sega R
    J Hypertens; 2010 May; 28(5):999-1006. PubMed ID: 20308922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of metabolic syndrome among hemodialysis patients according to NCEP-ATP III and IDF definitions.
    Ucar E; Huzmeli C; Guven O; Savas N; Gullu M; Asilyoruk S; Kuvandik C; Temizkan A; Kuvandik G
    Ren Fail; 2009; 31(3):221-8. PubMed ID: 19288328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association of metabolic syndrome components and diabetes mellitus: evidence from China National Stroke Screening and Prevention Project.
    Li W; Wang D; Wang X; Gong Y; Cao S; Yin X; Zhuang X; Shi W; Wang Z; Lu Z
    BMC Public Health; 2019 Feb; 19(1):192. PubMed ID: 30764803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs.
    Laforest L; Souchet T; Moulin P; Ritleng C; Desamericq G; Le Jeunne P; Schwalm MS; Van Ganse E
    Arch Cardiovasc Dis; 2009 Jan; 102(1):43-50. PubMed ID: 19233108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atherogenic dyslipidemia in the cardiometabolic syndrome.
    Govindarajan G; Chowdhury N; Flaker G
    J Cardiometab Syndr; 2006; 1(2):153-5. PubMed ID: 17679818
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.